Manvir K Hayer1, Ashwin Radhakrishnan2, Anna M Price1, Boyang Liu2, Shanat Baig2, Christopher J Weston3, Luca Biasiolli4, Charles J Ferro1, Jonathan N Townend2, Richard P Steeds2, Nicola C Edwards5. 1. Institute of Cardiovascular Science, University of Birmingham, Birmingham, United Kingdom; Department of Nephrology, Queen Elizabeth Hospital, Birmingham, United Kingdom. 2. Institute of Cardiovascular Science, University of Birmingham, Birmingham, United Kingdom; Department of Cardiology, Queen Elizabeth Hospital, Birmingham, United Kingdom. 3. NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, United Kingdom; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom. 4. Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. 5. Institute of Cardiovascular Science, University of Birmingham, Birmingham, United Kingdom; Green Lane Cardiovascular Service, Auckland, New Zealand. Electronic address: NicolaEd@adhb.govt.nz.
Abstract
OBJECTIVES: A proof of concept cross-sectional study investigating changes in myocardial abnormalities across stages of chronic kidney disease (CKD). Characterizing noninvasive markers of myocardial fibrosis on cardiac magnetic resonance, echocardiography, and correlating with biomarkers of fibrosis, myocardial injury, and functional correlates including exercise tolerance. BACKGROUND: CKD is associated with an increased risk of cardiovascular death. Much of the excess mortality is attributed to uremic cardiomyopathy, defined by increased left ventricular hypertrophy, myocardial dysfunction, and fibrosis. The prevalence of these abnormalities across stages of CKD and their impact on cardiovascular performance is unknown. METHODS: A total of 134 nondiabetic, pre-dialysis subjects with CKD stages 2 to 5 without myocardial ischemia underwent cardiac magnetic resonance (1.5-T) including; T1 mapping (biomarker of diffuse fibrosis), T2 mapping (edema), late gadolinium enhancement, and assessment of aortic distensibility. Serum biomarkers including collagen turnover (P1NP, P3NP), troponin T, and N-terminal pro-B-type natriuretic peptide were measured. Cardiovascular performance was quantified by bicycle cardiopulmonary exercise testing and echocardiography. RESULTS: Native myocardial T1 times increased incrementally from stage 2 to 5 (966 ± 21 ms vs. 994 ± 33 ms; p < 0.001), independent of hypertension and aortic distensibility. Left atrial volume, E/e', N-terminal pro-B-type natriuretic peptide, P1NP, and P3NP increased with CKD stage (p < 0.05), while effort tolerance (% predicted VO2Peak, %VO2VT) decreased (p < 0.001). In multivariable linear regression models, estimated glomerular filtration rate was the strongest predictor of native myocardial T1 time (p < 0.001). Native myocardial T1 time, left atrial dilatation, and high-sensitivity troponin T were independent predictors of % predicted VO2Peak (p < 0.001). CONCLUSIONS: Imaging and serum biomarkers of myocardial fibrosis increase with advancing CKD independent of effects of left ventricular afterload and might be a key intermediary in the development of uremic cardiomyopathy. Further studies are needed to determine whether these changes lead to the increased rates of heart failure and death in CKD. (Left Ventricular Fibrosis in Chronic Kidney Disease [FibroCKD]; NCT03176862).
OBJECTIVES: A proof of concept cross-sectional study investigating changes in myocardial abnormalities across stages of chronic kidney disease (CKD). Characterizing noninvasive markers of myocardial fibrosis on cardiac magnetic resonance, echocardiography, and correlating with biomarkers of fibrosis, myocardial injury, and functional correlates including exercise tolerance. BACKGROUND: CKD is associated with an increased risk of cardiovascular death. Much of the excess mortality is attributed to uremic cardiomyopathy, defined by increased left ventricular hypertrophy, myocardial dysfunction, and fibrosis. The prevalence of these abnormalities across stages of CKD and their impact on cardiovascular performance is unknown. METHODS: A total of 134 nondiabetic, pre-dialysis subjects with CKD stages 2 to 5 without myocardial ischemia underwent cardiac magnetic resonance (1.5-T) including; T1 mapping (biomarker of diffuse fibrosis), T2 mapping (edema), late gadolinium enhancement, and assessment of aortic distensibility. Serum biomarkers including collagen turnover (P1NP, P3NP), troponin T, and N-terminal pro-B-type natriuretic peptide were measured. Cardiovascular performance was quantified by bicycle cardiopulmonary exercise testing and echocardiography. RESULTS: Native myocardial T1 times increased incrementally from stage 2 to 5 (966 ± 21 ms vs. 994 ± 33 ms; p < 0.001), independent of hypertension and aortic distensibility. Left atrial volume, E/e', N-terminal pro-B-type natriuretic peptide, P1NP, and P3NP increased with CKD stage (p < 0.05), while effort tolerance (% predicted VO2Peak, %VO2VT) decreased (p < 0.001). In multivariable linear regression models, estimated glomerular filtration rate was the strongest predictor of native myocardial T1 time (p < 0.001). Native myocardial T1 time, left atrial dilatation, and high-sensitivity troponin T were independent predictors of % predicted VO2Peak (p < 0.001). CONCLUSIONS: Imaging and serum biomarkers of myocardial fibrosis increase with advancing CKD independent of effects of left ventricular afterload and might be a key intermediary in the development of uremic cardiomyopathy. Further studies are needed to determine whether these changes lead to the increased rates of heart failure and death in CKD. (Left Ventricular Fibrosis in Chronic Kidney Disease [FibroCKD]; NCT03176862).
Authors: Gary J Balady; Ross Arena; Kathy Sietsema; Jonathan Myers; Lola Coke; Gerald F Fletcher; Daniel Forman; Barry Franklin; Marco Guazzi; Martha Gulati; Steven J Keteyian; Carl J Lavie; Richard Macko; Donna Mancini; Richard V Milani Journal: Circulation Date: 2010-06-28 Impact factor: 29.690
Authors: P B Mark; N Johnston; B A Groenning; J E Foster; K G Blyth; T N Martin; T Steedman; H J Dargie; A G Jardine Journal: Kidney Int Date: 2006-05 Impact factor: 10.612
Authors: Dhrubo J Rakhit; Xiaohong H Zhang; Rodel Leano; Kirsten A Armstrong; Nicole M Isbel; Thomas H Marwick Journal: Am Heart J Date: 2007-04 Impact factor: 4.749
Authors: Matthew P M Graham-Brown; Daniel S March; Darren R Churchward; David J Stensel; Anvesha Singh; Ranjit Arnold; James O Burton; Gerry P McCann Journal: Kidney Int Date: 2016-10 Impact factor: 10.612
Authors: Boyang Liu; Ahmed M Dardeer; William E Moody; Manvir K Hayer; Shanat Baig; Anna M Price; Francisco Leyva; Nicola C Edwards; Richard P Steeds Journal: Int J Cardiovasc Imaging Date: 2017-11-27 Impact factor: 2.357
Authors: Manvir K Hayer; Ashwin Radhakrishnan; Anna M Price; Shanat Baig; Boyang Liu; Charles J Ferro; Gabriella Captur; Jonathan N Townend; James C Moon; Nicola C Edwards; Richard P Steeds Journal: Int J Cardiol Date: 2019-06-04 Impact factor: 4.164
Authors: Elaine Rutherford; Mohammed A Talle; Kenneth Mangion; Elizabeth Bell; Samuli M Rauhalammi; Giles Roditi; Christie McComb; Aleksandra Radjenovic; Paul Welsh; Rosemary Woodward; Allan D Struthers; Alan G Jardine; Rajan K Patel; Colin Berry; Patrick B Mark Journal: Kidney Int Date: 2016-08-05 Impact factor: 10.612
Authors: Alexander Grabner; Karla Schramm; Neerupma Silswal; Matt Hendrix; Christopher Yanucil; Brian Czaya; Saurav Singh; Myles Wolf; Sven Hermann; Jörg Stypmann; Giovana Seno Di Marco; Marcus Brand; Michael J Wacker; Christian Faul Journal: Sci Rep Date: 2017-05-16 Impact factor: 4.379
Authors: Francisco Vasques-Nóvoa; António Angélico-Gonçalves; José M G Alvarenga; João Nobrega; Rui J Cerqueira; Jennifer Mancio; Adelino F Leite-Moreira; Roberto Roncon-Albuquerque Journal: ESC Heart Fail Date: 2022-02-11